Telomerase and HER-2/neu as targets of genetic cancer vaccines in dogs

Daniela Peruzzi, Giuseppe Mesiti, Gennaro Ciliberto, Nicola La Monica, Luigi Aurisicchio

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Pet dogs represent a valuable pre-clinical model to assess the efficacy of oncology drugs. Additionally, canine cancers occur with an incidence similar to that of humans and share many features with human malignancies including histological appearance, tumor genetics, biological behavior and response to conventional therapies. The telomerase reverse transcriptase (TERT) is reactivated in most of human and dog tumors. Similarly, HER-2/neu oncoprotein is overexpressed in a proportion of canine breast cancers. Therefore, TERT and HER-2/neu can constitute valid tumor associated antigens (TAA), suitable targets for translational cancer immunotherapy in dogs. In this study, we have evaluated the ability of DNA electroporation (DNA-EP) and Adenovirus serotype 6 (Ad6) to induce immune responses against dog TERT (dTERT) and HER-2/neu in healthy dogs. Vaccination was effective in all treated animals and the adaptive immune response remained detectable and long-lasting in the absence of autoimmunity or other side-effects. Our results show that DNA-EP/Ad6-based cancer vaccine induces adaptive immune responses against TAA in canine subjects and support further evaluation of this approach in cancer dog patients.

Original languageEnglish
Pages (from-to)1201-1208
Number of pages8
JournalVaccine
Volume28
Issue number5
DOIs
Publication statusPublished - Feb 3 2010

Fingerprint

telomerase
Cancer Vaccines
Telomerase
Dogs
vaccines
neoplasms
dogs
Canidae
Neoplasms
Electroporation
RNA-directed DNA polymerase
Adaptive Immunity
Neoplasm Antigens
Adenoviridae
electroporation
Aptitude
Oncogene Proteins
DNA
Pets
serotypes

Keywords

  • Adenovirus
  • DNA-EP
  • Tumor immunity
  • Vaccination

ASJC Scopus subject areas

  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)
  • Molecular Medicine

Cite this

Telomerase and HER-2/neu as targets of genetic cancer vaccines in dogs. / Peruzzi, Daniela; Mesiti, Giuseppe; Ciliberto, Gennaro; La Monica, Nicola; Aurisicchio, Luigi.

In: Vaccine, Vol. 28, No. 5, 03.02.2010, p. 1201-1208.

Research output: Contribution to journalArticle

Peruzzi, D, Mesiti, G, Ciliberto, G, La Monica, N & Aurisicchio, L 2010, 'Telomerase and HER-2/neu as targets of genetic cancer vaccines in dogs', Vaccine, vol. 28, no. 5, pp. 1201-1208. https://doi.org/10.1016/j.vaccine.2009.11.031
Peruzzi, Daniela ; Mesiti, Giuseppe ; Ciliberto, Gennaro ; La Monica, Nicola ; Aurisicchio, Luigi. / Telomerase and HER-2/neu as targets of genetic cancer vaccines in dogs. In: Vaccine. 2010 ; Vol. 28, No. 5. pp. 1201-1208.
@article{2102397b4f0a41468458ad0af165404d,
title = "Telomerase and HER-2/neu as targets of genetic cancer vaccines in dogs",
abstract = "Pet dogs represent a valuable pre-clinical model to assess the efficacy of oncology drugs. Additionally, canine cancers occur with an incidence similar to that of humans and share many features with human malignancies including histological appearance, tumor genetics, biological behavior and response to conventional therapies. The telomerase reverse transcriptase (TERT) is reactivated in most of human and dog tumors. Similarly, HER-2/neu oncoprotein is overexpressed in a proportion of canine breast cancers. Therefore, TERT and HER-2/neu can constitute valid tumor associated antigens (TAA), suitable targets for translational cancer immunotherapy in dogs. In this study, we have evaluated the ability of DNA electroporation (DNA-EP) and Adenovirus serotype 6 (Ad6) to induce immune responses against dog TERT (dTERT) and HER-2/neu in healthy dogs. Vaccination was effective in all treated animals and the adaptive immune response remained detectable and long-lasting in the absence of autoimmunity or other side-effects. Our results show that DNA-EP/Ad6-based cancer vaccine induces adaptive immune responses against TAA in canine subjects and support further evaluation of this approach in cancer dog patients.",
keywords = "Adenovirus, DNA-EP, Tumor immunity, Vaccination",
author = "Daniela Peruzzi and Giuseppe Mesiti and Gennaro Ciliberto and {La Monica}, Nicola and Luigi Aurisicchio",
year = "2010",
month = "2",
day = "3",
doi = "10.1016/j.vaccine.2009.11.031",
language = "English",
volume = "28",
pages = "1201--1208",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "5",

}

TY - JOUR

T1 - Telomerase and HER-2/neu as targets of genetic cancer vaccines in dogs

AU - Peruzzi, Daniela

AU - Mesiti, Giuseppe

AU - Ciliberto, Gennaro

AU - La Monica, Nicola

AU - Aurisicchio, Luigi

PY - 2010/2/3

Y1 - 2010/2/3

N2 - Pet dogs represent a valuable pre-clinical model to assess the efficacy of oncology drugs. Additionally, canine cancers occur with an incidence similar to that of humans and share many features with human malignancies including histological appearance, tumor genetics, biological behavior and response to conventional therapies. The telomerase reverse transcriptase (TERT) is reactivated in most of human and dog tumors. Similarly, HER-2/neu oncoprotein is overexpressed in a proportion of canine breast cancers. Therefore, TERT and HER-2/neu can constitute valid tumor associated antigens (TAA), suitable targets for translational cancer immunotherapy in dogs. In this study, we have evaluated the ability of DNA electroporation (DNA-EP) and Adenovirus serotype 6 (Ad6) to induce immune responses against dog TERT (dTERT) and HER-2/neu in healthy dogs. Vaccination was effective in all treated animals and the adaptive immune response remained detectable and long-lasting in the absence of autoimmunity or other side-effects. Our results show that DNA-EP/Ad6-based cancer vaccine induces adaptive immune responses against TAA in canine subjects and support further evaluation of this approach in cancer dog patients.

AB - Pet dogs represent a valuable pre-clinical model to assess the efficacy of oncology drugs. Additionally, canine cancers occur with an incidence similar to that of humans and share many features with human malignancies including histological appearance, tumor genetics, biological behavior and response to conventional therapies. The telomerase reverse transcriptase (TERT) is reactivated in most of human and dog tumors. Similarly, HER-2/neu oncoprotein is overexpressed in a proportion of canine breast cancers. Therefore, TERT and HER-2/neu can constitute valid tumor associated antigens (TAA), suitable targets for translational cancer immunotherapy in dogs. In this study, we have evaluated the ability of DNA electroporation (DNA-EP) and Adenovirus serotype 6 (Ad6) to induce immune responses against dog TERT (dTERT) and HER-2/neu in healthy dogs. Vaccination was effective in all treated animals and the adaptive immune response remained detectable and long-lasting in the absence of autoimmunity or other side-effects. Our results show that DNA-EP/Ad6-based cancer vaccine induces adaptive immune responses against TAA in canine subjects and support further evaluation of this approach in cancer dog patients.

KW - Adenovirus

KW - DNA-EP

KW - Tumor immunity

KW - Vaccination

UR - http://www.scopus.com/inward/record.url?scp=74149094270&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=74149094270&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2009.11.031

DO - 10.1016/j.vaccine.2009.11.031

M3 - Article

C2 - 19944791

AN - SCOPUS:74149094270

VL - 28

SP - 1201

EP - 1208

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 5

ER -